EDP Sciences logo
Subscriber Authentication Point
Rechercher
Menu
Accueil Tous les numéros Volume 41 / Numéro 8-9 (Août-Septembre 2025) Med Sci (Paris), 41 8-9 (2025) 647-656 References
Open Access
Issue
Med Sci (Paris)
Volume 41, Number 8-9, Août-Septembre 2025
Page(s) 647 - 656
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2025098
Published online 8 septembre 2025
  1. Meinke G, Bohm A, Hauber J, et al. Cre recombinase and other tyrosine recombinases. Chem Rev 2016 ; 116 : 12785–820. [Google Scholar]
  2. Cody JP, Graham ND, Zhao C, et al. Site-specific recombinase genome engineering toolkit in maize. Plant Direct 2020 ; 4 : e00209. [Google Scholar]
  3. Pâques F, Duchateau P. Meganucleases and DNA double-strand break-induced recombination: perspectives for gene therapy. Curr Gene Ther 2007 ; 7 : 49–66. [Google Scholar]
  4. Dion S, Demattéi M-V, Renault S. Les domaines à doigts de zinc vers la modification de la structure et de l’activité des génomes. Med Sci (Paris) 2007 ; 23 : 834–9. [Google Scholar]
  5. Dupret B, Angrand P-O. L’ingénierie des génomes par les TALEN. Med Sci (Paris) 2014 ; 30 : 186–93. [Google Scholar]
  6. Tremblay JP. CRISPR, un système qui permet de corriger ou de modifier l’expression de gènes responsables de maladies héréditaires. Med Sci (Paris) 2015 ; 31 : 1014–22. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  7. Jordan B. CRISPR-Cas9, une nouvelle donne pour la thérapie génique. Med Sci (Paris) 2015 ; 31 : 1035–8. [Google Scholar]
  8. Gaudelli NM, Komor AC, Rees HA, et al. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature 2017 ; 551 : 464–71. [CrossRef] [PubMed] [Google Scholar]
  9. Wang D, Zhang Y, Zhang J, et al. Advances in base editing: a focus on base transversions. Mutat Res Rev Mutat Res 2024 ; 794 : 108515. [Google Scholar]
  10. Anzalone AV, Randolph PB, Davis JR, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 2019 ; 576 : 149–57. [CrossRef] [PubMed] [Google Scholar]
  11. Bouchard C, Godbout K, Tremblay JP. La correction de mutations pathogènes par Prime editing. Med Sci (Paris) 2024 ; 40 : 748–56. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  12. Gilbert LA, Larson MH, Morsut L, et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 2013 ; 154 : 442–51. [CrossRef] [PubMed] [Google Scholar]
  13. Kwon DY, Zhao Y-T, Lamonica JM, et al. Locus-specific histone deacetylation using a synthetic CRISPR-Cas9-based HDAC. Nat Commun 2017 ; 8 : 15315. [Google Scholar]
  14. Liu XS, Wu H, Ji X, et al. Editing DNA methylation in the mammalian genome. Cell 2016 ; 167 : 233–47.e17. [Google Scholar]
  15. Khabou H, Dalkara D. La conception de vecteurs adaptés à la thérapie génique oculaire. Med Sci (Paris) 2015 ; 31 : 529–37. [Google Scholar]
  16. Raguram A, Banskota S, Liu DR. Therapeutic in vivo delivery of gene editing agents. Cell 2022 ; 185 : 2806–27. [Google Scholar]
  17. Corbin A, Grigorov B, Roingeard P, et al. Réexamen de l’assemblage du VIH-1. Med Sci (Paris) 2008 ; 24 : 49–55. [Google Scholar]
  18. Gutierrez-Guerrero A, Cosset F-L, Verhoeyen E. Lentiviral vector pseudotypes: precious tools to improve gene modification of hematopoietic cells for research and gene therapy. Viruses 2020 ; 12 : 1016. [Google Scholar]
  19. Lyu P, Lu B. New advances in using virus-like particles and related technologies for eukaryotic genome editing delivery. IJMS 2022 ; 23 : 8750. [Google Scholar]
  20. Voelkel C, Galla M, Maetzig T, et al. Protein transduction from retroviral Gag precursors. Proc Natl Acad Sci U S A 2010 ; 107 : 7805–10. [Google Scholar]
  21. Mangeot PE, Risson V, Fusil F, et al. Genome editing in primary cells and in vivo using viral-derived Nanoblades loaded with Cas9-sgRNA ribonucleoproteins. Nat Commun 2019 ; 10 : 45. [Google Scholar]
  22. Urano E, Aoki T, Futahashi Y, et al. Substitution of the myristoylation signal of human immunodeficiency virus type 1 Pr55Gag with the phospholipase C-delta1 pleckstrin homology domain results in infectious pseudovirion production. J Gen Virol 2008 ; 89 : 3144–9. [Google Scholar]
  23. Haldrup J, Andersen S, Labial ARL, et al. Engineered lentivirus-derived nanoparticles (LVNPs) for delivery of CRISPR/Cas ribonucleoprotein complexes supporting base editing, prime editing and in vivo gene modification. Nucleic Acids Res 2023 ; 51 : 10059–74. [Google Scholar]
  24. Banskota S, Raguram A, Suh S, et al. Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell 2022 ; 185 : 250–65.e16. [Google Scholar]
  25. Halegua T, Risson V, Carras J, et al. Delivery of prime editing in human stem cells using pseudoviral NanoScribes particles. Nature Commun 4 ; 16 : 397. [Google Scholar]
  26. An M, Raguram A, Du SW, et al. Engineered virus-like particles for transient delivery of prime editor ribonucleoprotein complexes in vivo. Nat Biotechnol 2024 ; 42 : 1526–37. [Google Scholar]
  27. Gee P, Lung MSY, Okuzaki Y, et al. Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping. Nat Commun 2020 ; 11 : 1334. [Google Scholar]
  28. Prel A, Caval V, Gayon R, et al. Highly efficient in vitro and in vivo delivery of functional RNAs using new versatile MS2-chimeric retrovirus-like particles. Mol Ther Methods Clin Dev 2015 ; 2 : 15039. [Google Scholar]
  29. Mianné J, Nasri A, Van CN, et al. CRISPR/Cas9-mediated gene knockout and interallelic gene conversion in human induced pluripotent stem cells using non-integrative bacteriophage-chimeric retrovirus-like particles. BMC Biol 2022 ; 20 : 8. [Google Scholar]
  30. Lyu P, Javidi-Parsijani P, Atala A, et al. Delivering Cas9/sgRNA ribonucleoprotein (RNP) by lentiviral capsid-based bionanoparticles for efficient « hit-and-run » genome editing. Nucleic Acids Res 2019 ; 47 : e99. [Google Scholar]
  31. Jo D-H, Kaczmarek S, Shin O, et al. Simultaneous engineering of natural killer cells for CAR transgenesis and CRISPR-Cas9 knockout using retroviral particles. Mol Ther Methods Clin Dev 2023 ; 29 : 173–84. [Google Scholar]
  32. Hamilton JR, Tsuchida CA, Nguyen DN, et al. Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering. Cell Reports 2021 ; 35 : 109207. [Google Scholar]
  33. Indikova I, Indik S. Highly efficient « hit-and-run » genome editing with unconcentrated lentivectors carrying Vpr.Prot.Cas9 protein produced from RRE-containing transcripts. Nucleic Acids Res 2020 ; 48 : 8178–87. [Google Scholar]
  34. Ling S, Zhang X, Dai Y, et al. Customizable virus-like particles deliver CRISPR-Cas9 ribonucleoprotein for effective ocular neovascular and Huntington’s disease gene therapy. Nat Nanotechnol 2025 ; 20 : 5433–53. [Google Scholar]
  35. Gutierrez-Guerrero A, Abrey Recalde MJ, Mangeot PE, et al. Baboon envelope pseudotyped « Nanoblades » carrying Cas9/gRNA complexes allow efficient genome editing in human T, B, and CD34+ cells and knock-in of AAV6-encoded donor DNA in CD34+ cells. Front Genome Ed 2021 ; 3 : 604371. [Google Scholar]
  36. Pfeifer A, Brandon EP, Kootstra N, et al. Delivery of the Cre recombinase by a self-deleting lentiviral vector: efficient gene targeting in vivo. Proc Natl Acad Sci U S A 2001 ; 98 : 11450–5. [Google Scholar]
  37. Galla M, Will E, Kraunus J, et al. Retroviral pseudotransduction for targeted cell manipulation. Mol Cell 2004 ; 16 : 309–15. [Google Scholar]
  38. Segel M, Lash B, Song J, et al. Mammalian retrovirus-like protein PEG10 packages its own mRNA and can be pseudotyped for mRNA delivery. Science 2021 ; 373 : 882–9. [Google Scholar]
  39. Kaczmarczyk SJ, Sitaraman K, Young HA, et al. Protein delivery using engineered virus-like particles. Proc Natl Acad Sci U S A 2011 ; 108 : 16998–17003. [Google Scholar]
  40. Izmiryan A, Basmaciogullari S, Henry A, et al. Efficient gene targeting mediated by a lentiviral vector-associated meganuclease. Nucleic Acids Res 2011 ; 39 : 7610–9. [Google Scholar]
  41. Cai Y, Bak RO, Mikkelsen JG. Targeted genome editing by lentiviral protein transduction of zinc-finger and TAL-effector nucleases. Elife 2014 ; 3 : e01911. [Google Scholar]
  42. Bobis-Wozowicz S, Galla M, Alzubi J, et al. Non-integrating gamma-retroviral vectors as a versatile tool for transient zinc-finger nuclease delivery. Sci Rep 2014 ; 4 : 4656. [Google Scholar]
  43. Cavazzana M. Progrès de la thérapie génique dans les maladies génétiques du système hématopoïétique. Med Sci (Paris) 2022 ; 38 : 768–71. [Google Scholar]
  44. Dong W, Kantor B. Lentiviral vectors for delivery of gene-editing systems based on CRISPR/Cas: current state and perspectives. Viruses 2021 ; 13 : 1288. [Google Scholar]
  45. Carpenter MA, Law EK, Serebrenik A, et al. A lentivirus-based system for Cas9/gRNA expression and subsequent removal by Cre-mediated recombination. Methods 2019 ; 156 : 79–84. [Google Scholar]
  46. Wang T, Birsoy K, Hughes NW, et al. Identification and characterization of essential genes in the human genome. Science 2015 ; 350 : 1096–101. [Google Scholar]
  47. Zhou Y, Zhu S, Cai C, et al. High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. Nature 2014 ; 509 : 487–91. [Google Scholar]
  48. Taha EA, Lee J, Hotta A. Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges. J Control Release 2022 ; 342 : 345–61. [Google Scholar]
  49. Baron Y, Sens J, Lange L, et al. Improved alpharetrovirus-based Gag.MS2 particles for efficient and transient delivery of CRISPR-Cas9 into target cells. Mol Ther Nucleic Acids 2022 ; 27 : 810–23. [Google Scholar]
  50. Tiroille V, Krug A, Bokobza E, et al. Nanoblades allow high-level genome editing in murine and human organoids. Mol Ther Nucleic Acids 2023 ; 33 : 57–74. [Google Scholar]
  51. Ngo W, Peukes J, Baldwin A, et al. Mechanism-guided engineering of a minimal biological particle for genome editing. Proc Natl Acad Sci U S A 2025 ; 122 : e2413519121. [Google Scholar]
  52. Dupressoir A, Heidmann T. Les syncytines — Des protéines d’enveloppe rétrovirales capturées au profit du développement placentaire. Med Sci (Paris) 2011 ; 27 : 163–9. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  53. Hindi SM, Petrany MJ, Greenfeld E, et al. Enveloped viruses pseudotyped with mammalian myogenic cell fusogens target skeletal muscle for gene delivery. Cell 2023 ; 186 : 3520. [Google Scholar]
  54. Strebinger D, Frangieh CJ, Friedrich MJ, et al. Cell type-specific delivery by modular envelope design. Nat Commun 2023 ; 14 : 5141. [Google Scholar]
  55. Hamilton JR, Chen E, Perez BS, et al. In vivo human T cell engineering with enveloped delivery vehicles. Nat Biotechnol 2024 ; 42 : 1684–92. [Google Scholar]
  56. Raguram A, An M, Chen PZ, et al. Directed evolution of engineered virus-like particles with improved production and transduction efficiencies. Nat Biotechnol 2024. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.